Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter

Documenti analoghi

• Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A
  di: Repessé, Yohann, et al.
  Pubblicazione: (2019)
• Influence of factor VIII level and its inhibitor titer on the therapeutic response to corticosteroids alone in the management of acquired hemophilia: A retrospective single-center study
  di: Vautier, Mathieu, et al.
  Pubblicazione: (2016)
• Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A
  di: Calvez, Thierry, et al.
  Pubblicazione: (2018)
• Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A
  di: Bachelet, Delphine, et al.
  Pubblicazione: (2019)
• International recommendations on the diagnosis and treatment of acquired hemophilia A
  di: Tiede, Andreas, et al.
  Pubblicazione: (2020)